Research Article

Delta-Like-1 Changes the Immunomodulatory Property of OP9 Cells

Lei Zhang,1,2,3 Rui-Jie Dang,2 Yan-Mei Yang,2 Dian-Chao Cui,4 Ping Li,2 Yan-Li Ni,5 Tong Hao,2 Changyong Wang,2 Xiao-Xia Jiang,2 and Nan-Zhu Fang1

1Laboratory of Animal Genetic Breeding and Reproduction, Yanbian University, Yanji, Jilin 133002, China
2Department of Advanced Interdisciplinary Studies, Institute of Basic Medical Sciences, 27 Taiping Road, Haidian District, Beijing 100850, China
3Department of Biology and Chemical Engineering, Tongren University, Tongren, Guizhou 554300, China
4Beijing Aiyuhua Hospital for Children and Women, 2 South Street, Beijing Economic and Technological Development Zone, Beijing 100176, China
5307-Ivy Translational Medicine Center, Laboratory of Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China

Correspondence should be addressed to Xiao-Xia Jiang; smi lovjiang@163.com and Nan-Zhu Fang; nzfang@ybu.edu.cn

Received 29 January 2015; Revised 10 April 2015; Accepted 20 April 2015

Academic Editor: Vladislav Volarevic

Copyright © 2016 Lei Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

As stromal cells and recently confirmed mesenchymal stem cells, OP9 cells support hematopoiesis stem cell (HSC) differentiation into the B lymphocyte lineage, yet Delta-like-1 (DL1) overexpressing OP9 (OP9DL1) cells promote the development of early T lymphocytes from HSC. However, the immunomodulatory capacity of OP9 or OP9DL1 on mature B and T cell proliferation has not been elucidated. Here, we show that OP9 and OP9DL1 have similar proliferation capacities and immunophenotypes except DL1 expression. Compared with OP9, OP9DL1 displayed more osteogenesis and less adipogenesis when cultured in the respective induction media. Both OP9 and OP9DL1 inhibited mature B and T cell proliferation. Furthermore, OP9 showed stronger inhibition on B cell proliferation and OP9DL1 exhibited stronger inhibition on T cell proliferation. With stimulation, both OP9 and OP9DL1 showed increased nitrate oxide (NO) production. The NO levels of OP9 were higher than that of OP9DL1 when stimulated with TNFα/IFNγ or LPS/IL4. Taken together, our study reveals a previously unrecognized role of OP9 and OP9DL1 in mature B and T cell proliferation. DL1 overexpression alone changed the properties of OP9 cells in addition to their role in early B cell development.

1. Introduction

The process of lymphocyte lineage differentiation and development from hematopoietic stem cells is highly influenced by soluble factors and cell contact-dependent signals within specific microenvironments, each of which supports the development of specific cell lineages. The bone marrow (BM) microenvironment supports B cell, but not T cell, lymphopoiesis [1], whereas the thymic environment is required for early T lymphocyte development [2]. In vitro, some BM-derived stromal cell lines have been applied to the formation of multiple hematopoietic cell lineages. One such cell line, OP9 stromal cells, has been found to support the development of multiple lineages, such as B cells, erythroid, and myeloid [3–5]; however, attempts to generate T cells from HSCs in vitro in the absence of the thymic microenvironment have been unsuccessful. The Notch signaling pathway is known to affect the developmental process of a variety of cell lineages [6–8]. When the OP9 cell line was retrovirally transduced to express the Notch ligand Delta-like-1 (namely, OP9DL1 cell line), it strongly promoted T cell lineage commitment and development and inhibited B cell lymphopoiesis in vitro [9].

Studies on the OP9 cell line demonstrated that OP9 are genuine mesenchymal stem cells (MSCs) with a multiple differentiation ability and immunomodulation capacity [10].
MSCs are multipotent stem cells capable of differentiating into multiple cell types, including osteoblasts and adipocytes, and can also regulate immune cell responses [11, 12]. Recently, a body of evidence [13–17] has indicated that MSCs produce a variety of cytokines such as nitric oxide (NO) and PGE\textsubscript{2} that display profound immunoregulatory properties by inhibiting the proliferation and function of several major types of immune cells, including natural killer cells, dendritic cells, and both T and B lymphocytes [18–20]. However, the underlying mechanisms of MSC immunomodulation have yet to be fully elucidated.

To date, studies on the effects of OP9 or OP9DL1 on T and B cells mainly focus on lineage commitment, differentiation, and function [7, 21, 22]. However, given the immunomodulatory properties of MSCs, the role of OP9 or OP9DL1 on mature T and B cell proliferation has not been investigated, which may be highly impressive considering the possible application of OP9 or OP9DL1 to T and B lymphocytes in ex vivo regeneration and expansion.

In this study, our results provide insight into the role of Delta-like-1 (DL1) in the properties of OP9. In addition to their different roles in promoting B or T cell development, OP9 and OP9DL1 show different capacities in inhibiting mature B or T cell proliferation.

2. Materials and Methods

2.1. Animals. C57BL/6 mice were purchased from the Laboratory Animal Center, Institute of Basic Medical Sciences, Beijing, China. Mice were maintained in a pathogen-free barrier facility, and all experiments were performed in accordance with the Institute of Basic Medical Sciences Guide for Laboratory Animals.

2.2. Cells. OP9 cells and Delta-like-1 overexpressing OP9 (OP9DL1) cell lines were gifts from Professor Bing Liu of Chinese PLA 307 Hospital [10] and were cultured in alpha minimum essential medium (\(\alpha\)-MEM, Gibco) with 4 mM L-glutamine, 100 U/mL penicillin, 100 U/mL streptomycin, and 20% fetal bovine serum (FBS) in a humidified atmosphere of 5% CO\textsubscript{2} at 37°C. Bone marrow cells, flushed out from femurs and tibiae of 2–3-week-old mice, were filtered by 40 \(\mu\)m cell strainer and subsequently subjected to BD phamlyse to remove red blood cells. CD34\textsuperscript{+} cells were then selected from the bone marrow monocytes by CD34 MicroBead Kit (Miltenyi Biotec) and incubated together with OP9 and OPDLI at ratio of 1:10 (OP9 or OP9DL1:CD34\textsuperscript{+} cells) in the \(\alpha\)-MEM with 5 ng/mL Flt3L, 5 ng/mL IL-7, and 20% FBS. Peripheral T and B cells were isolated from murine spleens with CD3e MicroBead Kit (Miltenyi Biotec) or B220 MicroBead Kit (Miltenyi Biotec), respectively. Next, the cells were activated with 1640 media containing 20% FBS in the presence of different stimulators (for T cells: PMA (50 ng/mL)/ion (1 \(\mu\)g/mL); for B cells: IL4 (25 ng/mL)/LPS (10 \(\mu\)g/mL)) for 24 h and then cultured alone or together with OP9 or OP9DL1 cells at different ratios for 36 h.

2.3. Cell Proliferation Assay. Cell proliferation was measured by BrdU incorporation and Ki67 assay. For BrdU incorporation, cells (1 \(\times\) 10\textsuperscript{5}/well) were seeded in 6-well plate, 10 mM BrdU (BD) was added and incubated for 3 hours, and then the cells were collected and processed according to the protocol of BrdU flow kit (BD Pharmingen, San Diego, CA, USA). For Ki67 assay, cells (1 \(\times\) 10\textsuperscript{5}/well) were seeded in 6-well plate, and 2 days later the cells were harvested and did according to the protocol of Ki67 Cell Proliferation Kit (Miltenyi Biotec Inc., Auburn, CA, USA). Data were collected on FACS Canto II (BD) and were analyzed with FlowJo software (TreeStar).

2.4. CFSE Staining. Peripheral CD3\textsuperscript{+} T or B220\textsuperscript{+} B cells were labeled with 5 \(\mu\)M carboxy fluorescein diacetate succinimidy ester (CFSE, Invitrogen) for 7 min at 4°C. Labeling was terminated according to the manufacturer’s protocol. After washing, cells were activated with stimulation factors as mentioned above for 24 h and then cultured with OP9 or OP9DL1. Cell division, as indicated by reduction of fluorescence intensity, was analyzed by flow cytometry.

2.5. Flow Cytometry. Antibodies anti-mouse CD29 (BD Pharmingen), CD31 (BioLegend), CD34 (BD Pharmingen), CD44 (BD Pharmingen), CD105 (BioLegend), CD45 (BD Pharmingen), Sca-1 (BioLegend), DL1 (BD Pharmingen), B220 (BD Pharmingen), and CD3 (BD Pharmingen) were used for this study. The Ki67 kit was from Miltenyi Biotec Inc. (Auburn, CA, USA) and BrdU flow kit was from BD Pharmingen (San Diego, CA, USA). Data were collected on FACS Canto II (BD) and were analyzed with FlowJo software (TreeStar).

2.6. In Vitro Differentiation. For in vitro differentiation, cells were induced with osteogenic induction media containing 0.1 mM dexamethasone, 50 mM ascorbate-2 phosphate, and 10 mM glyceraldehyde 3-phosphate (Sigma). To induce adipogenic differentiation, cells were cultured in an adipogenic induction media containing 1 mM dexamethasone, 200 mM indomethacin, 0.5 mM 3-isobutyl-1-methyl-xanthine, and 10 \(\mu\)g/mL insulin (Sigma). Alkaline phosphatase (ALP) assay and Oil Red O staining were performed as described previously.

2.7. Detection of NO. OP9 and OP9DL1 were stimulated with TNF\textalpha/INF\gamma, LPS/IL4, or PMA/ion for 6, 12, and 24 h, respectively. NO in culture supernatants was detected using a modified Griess reagent (Sigma-Aldrich). Briefly, all NO\textsubscript{3} was converted into NO\textsubscript{2} by nitrate reductase, and total NO\textsubscript{2} was detected by the Griess reaction.

2.8. Real-Time PCR. Total RNA was extracted with TRI-ZOL (Sigma) and reverse transcribed into cDNA with a reverse transcriptase kit (Takara). cDNA was used as a template in real-time PCR with SYBR Green reagent from TOYOBO (Shanghai, China) to determine specific
gene expression. Primer sequences were as follows: β-actin: CTCTCGGCTTATACCTT (forward) and AAAGCCTTACATCAAG (reverse); EBFI: ATGAAGAGGTTG-GATTCTG (forward) and GCAGTTATTGGTGATTTCC (reverse); GATA3: CTGTCAAGACCAAACAC (forward) and CACACTCTTGATAGTCAACC (reverse).

2.9. Statistical Analysis. Data are presented as mean ± SD. Statistical significance was assessed by unpaired two-tailed Student's t-test.

3. Results

3.1. The Immunophenotypes and the Proliferation Properties of OP9 and OP9DL1. It has been demonstrated that the OP9 cell line is genuine MSCs [10]. To examine whether OP9 cells overexpressing DLI show a different immunophenotype than conventional OP9 cells, we analyzed surface markers indicated in Figure 1(a). The flow cytometric data showed that DL1 expression in OP9DL1 cells is significantly higher than that in OP9 cells. MSC surface molecules including CD29, CD44, and Sca-1 were positive in both OP9 and OP9DL1 cells, while MSCs surface molecules CD105, hematopoietic lineage markers CD34 and CD45, and endothelial cell marker CD31 were almost absent in both OP9 and OP9DL1 cell lines. Next, we examined the proliferation ability of OP9 and OP9DL1 by Ki67 and BrdU labeling assays, respectively. The growth rate between OP9 and OP9DL1 did not differ significantly (Figures 1(b) and 1(c)).

3.2. Different Differentiation Capacities of OP9 and OP9DL1. Recently, there has been some debate on the effects of Notch receptor/ligand interaction on the differentiation of MSC into the osteocyte and adipocyte lineages [23, 24]. To investigate the effect of DLI on OP9 differentiation, we examined the adipogenesis and osteogenesis of OP9 and OP9DL1 at different time intervals as indicated in Figures 2(a) and 2(b). Oil Red O staining revealed that the rate of adipocyte differentiation of OP9 cells was faster than that of OP9DL1 at each of the indicated time points (Figure 2(a)). Conversely, osteogenesis of OP9DL1 was more robust compared with that of OP9 cells, as determined by ALP staining (Figure 2(b)).

3.3. OP9 Supports the Development of BM CD34+ Cells to B Cells, Whereas OP9DL1 Promotes the Differentiation of CD34+ Cells to T Cells. To examine the ability of OP9 and OP9DL1 to support BM CD34+ cell differentiation to B or T lymphoid lineages, coculture experiments of CD34+ cells with OP9 or OP9DL1 were performed. CD34+ cells were isolated from the femurs and tibiae of 2- to 3-week-old mice and were cultured with either OP9 or OP9DL1. The cells were collected and FACs analysis was performed at day 12 of coculture. As shown in Figures 3(a) and 3(b), there were B220+ cells in CD34+ cells with OP9 coculture and CD34+ cells with CD34+ cells with OP9DL1 coculture. Real-time PCR was used to determine the expression of EBF1 (B cell factor) or GATA3 (T cell factor). As expected, high EBF1 expression was found in the OP9 coculture group whereas high GATA3 expression was found in the OP9DL1 coculture group (Figures 3(c) and 3(d)). Similar to previous reports [5, 9], our results suggest that OP9 supports early B lymphocyte lineage development from CD34+ while OP9DL1 promotes early T cell growth.

3.4. The Effect of OP9 and OP9DL1 on the Proliferation of Mature B Cells. The impact of OP9 or OP9DL1 on mature B cell proliferation has yet to be defined. Splenic B220+ B cells were stained with CFSE and then incubated alone or together with OP9 or OP9DL1 at different ratios (OP9 or OP9DL1 versus B cells) in the presence of LPS plus IL4, respectively. As shown in Figure 4, both OP9 and OP9DL1 inhibit mature B cell proliferation as indicated by the reduction in CFSE intensity. Compared with OP9DL1, OP9 exhibited a much stronger immunosuppressive activity, and B cell proliferation was strikingly inhibited by OP9 at ratios as low as 1:80 (OP9 to B).

3.5. The Effect of OP9 and OP9DL1 on the Proliferation of Mature T Cells. As mentioned earlier, OP9DL1 promotes early T cell development, but its effect on mature T cell proliferation is unknown. To clarify the role of OP9DL1 on mature T cell growth, CD3+ T cells stained with CFSE were cultured alone or together with OP9 or OP9DL1 cells at the indicated ratios (Figure 5). Mature T cell proliferation was directly assessed by CFSE labeling and monitoring of CFSE dilution. Unexpectedly, a marked reduction in T cell proliferation in the OP9DL1 cultures was observed compared with that in coculture with OP9 at each proportional hierarchy (Figure 5). Compared with the growth rate of T cells alone, OP9DL1 inhibits T cell proliferation more obviously with increasing ratios (OP9DL1 versus T cell), while OP9 only prohibits T cell growth at the highest ratio.

3.6. NO Production in OP9 and OP9DL1 Cells in the Presence of Different Stimulators. NO has been shown to be involved in the immunomodulation of MSCs to multiple immune cells [11]. To examine whether NO is related to the effect of OP9 and OP9DL1 on mature B or T cell proliferation, we assayed the NO level in culture supernatants from OP9 and OP9DL1 stimulated with TNFα/IFNγ, LPS/IL4, or PMA/ion for 6, 12, and 24 h, respectively (Figure 6). Our data showed that NO production was indeed increased in the culture media from each group of stimulation factors, regardless of stimulation duration of OP9 or OP9DL1, as compared with that of the no stimulation group. The NO levels of OP9 were higher than that of OP9DL1 when stimulated with TNFα/IFNγ or LPS/IL4 (Figure 6).

4. Discussion

It has been extensively demonstrated that OP9 promotes B lymphocyte lineage development and OP9DL1 contributes to the development of early T cells at the expense of B cell development [5, 9, 21, 25]. However, it was still unclear what role both OP9 and OP9DL1 cells have on mature T and B cell proliferation, respectively. Our findings demonstrated for the first time that OP9 exhibited strong immunosuppressive
Figure 1: Comparisons between OP9 and OP9DL1 cells with regard to their immunophenotype and proliferation. (a) The indicated surface markers of OP9 or OP9DL1 cells were shown by FACS analysis, respectively. (b)-(c) The growth rate of OP9 and OP9DL1 cells was assayed by Ki67 or BrdU incorporation assays, respectively.
activity on mature B cell proliferation, while OP9DL1 showed enhanced inhibition capacity on mature T cell proliferation.

It is known that Notch1 engagement by Notch ligand D1 can activate Notch1 signaling [7, 26, 27], and the Notch1 pathway regulates T and B lineage commitment and development [25, 28, 29]. It has been shown that inhibition of Notch signaling decreases CD4 or CD8 T cell proliferation [30] but has no effect on mature B cell growth [31]. To date, the effect of OP9 and OP9DL1 on mature T and B cell proliferation has not been clarified. Surprisingly, our data showed that OP9DL1 inhibits mature T cell proliferation and defers mature B cells growth (Figures 4 and 5), which is different from its role in early T and B cell development [9, 25]. In addition, in light of the contribution of OP9 to early B cell development, OP9 should also support mature B cells proliferation; however, we found that OP9 impeded the proliferation of mature B cells (Figure 4). These unforeseen results may be associated with the different responses of mature T/B cells to OP9 or OP9DL1 immunomodulation. In accordance with a previous report [10], our study shows that both OP9 and OP9DL1 have the same proliferation capacity and phenotypes similar to those of MSCs (Figure 1) and also differentiation capacities to adipocytes and osteoblasts in vitro. (a) Differentiation into adipocytes was shown by Oil Red O staining at the indicated time points, respectively. (b) The osteogenesis of OP9 and OP9DL1 was assayed by ALP staining at different times, respectively.

MSCs possess an immunomodulatory role on immune cells including T and B cells by direct cell-to-cell contact-dependent mechanisms [32, 33] and/or the production of soluble factors, such as indoleamine 2,3-deoxigenase [34], prostaglandin E2 [16–18], NO [11, 35, 36], TGFβ [37], hepatocyte growth factor [37], IL-10 [38], IFNγ [39], and TNFα [15]. It has been reported that D1L activates Notch signaling [7] and Notch activation may be associated with increased NO production [40]. Our data showed that OP9DL1 did not generate more NO than OP9, and more NO is produced from the OP9 or OP9DL1 stimulation groups compared with that of the no simulation group. These results suggest that NO may be involved in regulating the growth of mature B and T cells during coculture with OP9 or OP9DL1. However, OP9DL1
Figure 3: Effect of OP9 or OP9DL1 on differentiation of bone marrow CD34+ cells. OP9 or OP9DL1 cells (5 × 10⁴/well) were plated in 12-well plates with α-MEM medium plus 20% FBS 12 h prior to the addition of BM CD34+ (5 × 10⁵/well). The coculture was started with α-MEM medium plus 20% FBS containing a final concentration of 5 ng/mL each of IL-7 and Flt-3 ligand (Flt-3L). 12 days later, cells were collected for FACS analysis ((a) and (b)), and EBF1 or GATA3 gene expression was determined by real-time PCR after 5-day coculture, respectively ((c) and (d)). (Error bars present the SD of the mean values, **P < 0.01.)
Figure 4: The effect of OP9 and OP9DL1 on proliferation of mature B cells. The B cells (B220+) isolated from mice spleens were stained with CFSE, then exposed with 25 ng/mL IL4 plus 10 μg/mL LPS for 24 h, and subsequently cultured alone or together with OP9 or OP9DL1 cells at different rates for 36 h. At 36 h later, the morphology of B cells in each well was observed microscopically (a), then the B cells were analyzed by FACS, and proliferation was measured by the reduction in CFSE intensity. Cell growth rates are indicated by percentages in (b). Data are representative of three experiments.

inhibits mature T cells more and mature B cells less than OP9, which may indicate that DL1 contributes to the dominant immunomodulation role in a cell contact-dependent fashion.

Similar to previous studies, in our study, more B cells and less T cells are generated from CD34+ cells in the OP9 coculture compared to the OP9-DL1 coculture group. Unlike
mature T/B cells, the cell-cell contact may have a predominant role in early T/B development during coculture with OP9 or OP9DL1. Certainly, the underlying immunomodulatory mechanism of OP9 and OP9DL1 to mature T/B cells remains to be defined in further studies.

5. Conclusion

Our study elucidated that DL1 changes the immunomodulation of MSCs to immune cells, showing potent inhibition of mature T cell proliferation and a slight delay in mature B cell proliferation.
Figure 6: NO production in OP9 and OP9DL1 cells in the presence of different stimulators. OP9 and OP9DL1 were stimulated with TNFα/IFNγ (each 2 ng/mL), LPS (10 μg/mL)/IL4 (25 ng/mL), or PMA (50 ng/mL)/ion (1 μg/mL) for 24 h, respectively. Supernatants were collected at 6, 12, and 24 h and used for NO assay, respectively.

Conflict of Interests

The authors declare no potential conflict of interests.

Authors’ Contribution

Xiao-Xia Jiang and Nan-Zhu Fang conceived and designed the experiments. Lei Zhang, Rui-Jie Dang, Yan-Mei Yang, Dian-Chao Cui, Ping Li, Yan-Li Ni, Tong Hao, Changyong Wang, Xiao-Xia Jiang, and Nan-Zhu Fang analyzed the data. Changyong Wang, Xiao-Xia Jiang, and Nan-Zhu Fang contributed reagents/materials/analysis tools. Lei Zhang, Rui-Jie Dang, Xiao-Xia Jiang, and Nan-Zhu Fang wrote the paper. Lei Zhang and Rui-Jie Dang contributed equally to this work.

Acknowledgments

The authors thank Bing Liu for providing valuable reagents and Lindsey Jones (Keck School of Medicine, University of Southern California) for her critical reading of the paper. This study was supported by Grants from the National Natural Science Foundation of China (81271936, 31200733).
and Program of International Scientific and Technological Cooperation and Exchanges of China (no. 2013DFG30680).

References

[1] D. G. Osmond, “Production and selection of B lymphocytes in bone marrow: lymphostromal interactions and apoptosis in normal, mutant and transgenic mice,” Advances in Experimental Medicine and Biology, vol. 355, pp. 15–20, 1994.

[2] G. Anderson, N. C. Moore, J. J. T. Owen, and E. J. Jenkins, “Cellular interactions in thymocyte development,” Annual Review of Immunology, vol. 14, pp. 73–99, 1996.

[3] T. Nakano, “In vitro development of hematopoietic system from mouse embryonic stem cells: a new approach for embryonic hematopoiesis,” International Journal of Hematology, vol. 65, no. 1, pp. 1–8, 1996.

[4] A. Suzuki and T. Nakano, “Development of hematopoietic cells from embryonic stem cells,” International Journal of Hematology, vol. 73, no. 1, pp. 1–5, 2001.

[5] J. R. Carlyle, A. M. Michie, C. Furlonger et al., “Identification of a novel developmental stage marking lineage commitment of progenitor thymocytes,” The Journal of Experimental Medicine, vol. 186, no. 2, pp. 173–182, 1997.

[6] J. S. Yuan, P. C. Kousis, S. Suliman, I. Visan, and C. J. Guidos, “Functions of notch signaling in the immune system: consensus and controversies,” Annual Review of Immunology, vol. 28, pp. 343–365, 2010.

[7] F. Radtke, N. Fasnacht, and H. R. MacDonald, “Notch signaling in the immune system,” Immunity, vol. 32, no. 1, pp. 14–27, 2010.

[8] K. Tanigaki and T. Honjo, “Regulation of lymphocyte development by Notch signaling,” Nature Immunology, vol. 8, no. 5, pp. 451–456, 2007.

[9] T. M. Schmitt and J. C. Zúñiga-Pflücker, “Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro,” Immunity, vol. 17, no. 6, pp. 749–756, 2002.

[10] J. Gao, X.-L. Yan, R. Li et al., “Characterization of OP9 as authentic mesenchymal stem cell line,” Journal of Genetics and Genomics, vol. 37, no. 7, pp. 475–482, 2010.

[11] G. Ren, L. Zhang, X. Zhao et al., “Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide,” Cell Stem Cell, vol. 2, no. 2, pp. 141–150, 2008.

[12] G. Xu, L. Zhang, G. Ren et al., “Immunosuppressive properties of cloned bone marrow mesenchymal stem cells,” Cell Research, vol. 17, no. 3, pp. 240–248, 2007.

[13] E. J. Bassi, D. C. de Almeida, P. M. M. Moraes-Vieira, and N. O. S. Câmara, “Exploring the role of soluble factors associated with immune regulatory properties of mesenchymal stem cells,” Stem Cell Reviews and Reports, vol. 8, no. 2, pp. 329–342, 2012.

[14] B. Kristjánsson and S. Hansaek, “Current perspectives in mesenchymal stem cell therapies for osteoarthritis,” Stem Cells International, vol. 2014, Article ID 194318, 13 pages, 2014.

[15] A. Dorronsoro, I. Ferrin, J. M. Salcedo et al., “Human mesenchymal stromal cells modulate T-cell responses through TNF-α-mediated activation of NF-κB,” European Journal of Immunology, vol. 44, no. 2, pp. 480–488, 2014.

[16] J. W. Kang, K.-S. Kang, H. C. Koo, J. R. Park, E. W. Choi, and Y. H. Park, “Soluble factors-mediated immunomodulatory effects of canine adipose tissue-derived mesenchymal stem cells,” Stem Cells and Development, vol. 17, no. 4, pp. 681–693, 2008.

[17] K. Chen, D. Wang, W. T. Du et al., “Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism,” Clinical Immunology, vol. 135, no. 3, pp. 448–458, 2010.

[18] S. Aggarwal and M. F. Pittenger, “Human mesenchymal stem cells modulate allogeneic immune cell responses,” Blood, vol. 105, no. 4, pp. 1815–1822, 2005.

[19] A. J. Nauta and W. E. Fibbe, “Immunomodulatory properties of mesenchymal stromal cells,” Blood, vol. 110, no. 10, pp. 3499–3506, 2007.

[20] X.-X. Jiang, Y. Zhang, B. Liu et al., “Human mesenchymal stem cells inhibit differentiation and function of monocYTE-derived dendritic cells,” Blood, vol. 105, no. 10, pp. 4120–4126, 2005.

[21] M. de Smedt, I. Hoebeke, and J. Plum, “Human bone marrow CD34+ progenitor cells mature to T cells on OP9-DL1 stromal cell line without thymus microenvironment,” Blood Cells, Molecules, and Diseases, vol. 33, no. 3, pp. 227–232, 2004.

[22] T. Palaga, L. Miele, T. E. Golde, and B. A. Osborne, “TCR-mediated Notch signaling regulates proliferation and IFN-γ production in peripheral T cells,” The Journal of Immunology, vol. 171, no. 6, pp. 3019–3024, 2003.

[23] M.-L. Nueda, V. Baladrón, B. Sánchez-Solana, M.-Á. Balles, M.-L. Nueda, and V. Baladrón, B. Sánchez-Solana, M.-Á. Balles, “The EGF-like protein dkk1 inhibits notch signaling and potentiates adipogenesis of mesenchymal cells,” Journal of Molecular Biology, vol. 367, no. 5, pp. 1281–1293, 2007.

[24] Y. Huang, X. Yang, Y. Wu et al., “γ-secretase inhibitor induces adipogenesis of adipose-derived stem cells by regulation of Notch and PPAR-γ,” Cell Proliferation, vol. 43, no. 2, pp. 147–156, 2010.

[25] S. Kutleša, J. Zayas, A. Valle, R. B. Levy, and R. Jurecic, “T-cell differentiation of multipotent hematopoietic cell line EML in the OP9-DL1 coculture system,” Experimental Hematology, vol. 37, no. 8, pp. 909.e1–923.e1, 2009.

[26] E. H. Schroeter, J. A. Kisslinger, and R. Kopan, “Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain,” Nature, vol. 393, no. 6683, pp. 382–386, 1998.

[27] G. Struhl and A. Adachi, “Nuclear access and action of Notch in vivo,” Cell, vol. 93, no. 4, pp. 649–660, 1998.

[28] M. A. Santos, L. M. Sarmento, M. Rebolo et al., “Notch signaling involves Delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 39, pp. 15454–15459, 2007.

[29] J. C. Pui, D. Allman, L. Xu et al., “Notch signaling in early lymphopoiesis influences B versus T lineage determination,” Immunity, vol. 11, no. 3, pp. 299–308, 1999.

[30] T. Taghon, I. D. Van Walle, G. De Smet et al., “Notch signaling is required for proliferation but not for differentiation at a well-defined β-selection checkpoint during human T-cell development,” Blood, vol. 113, no. 14, pp. 3254–3263, 2009.

[31] J.-C. Kang, W.-S. Kim, and S.-G. Park, “Notch signaling in early development: a well-defined β-selection checkpoint in human T-cell development,” The Journal of Experimental Medicine, vol. 11, no. 3, pp. 322–334, 2014.

[32] C. Chen, K. Akiyama, T. Yamazaki et al., “Telomerase governs immunomodulatory properties of mesenchymal stem cells by regulating FAS ligand expression,” EMBO Molecular Medicine, vol. 6, no. 3, pp. 322–334, 2014.

[33] M. M. Duffy, J. Pindjakova, S. A. Hanley et al., “Mesenchymal stem cell inhibition of T-helper 17 cell differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via...
the EP4 receptor,” *European Journal of Immunology*, vol. 41, no. 10, pp. 2840–2851, 2011.

[34] R. Meisel, A. Zibert, M. Laryea, U. Göbel, W. Däubener, and D. Dilloo, “Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation,” *Blood*, vol. 103, no. 12, pp. 4619–4621, 2004.

[35] K. Sato, K. Ozaki, I. Oh et al., “Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells,” *Blood*, vol. 109, no. 1, pp. 228–234, 2007.

[36] L. Zhang, R.-J. Dang, H. Li et al., “SOCS1 regulates the immune modulatory properties of mesenchymal stem cells by inhibiting nitric oxide production,” *PLoS ONE*, vol. 9, no. 5, Article ID e97256, 2014.

[37] M. D. Nicola, C. Carlo-Stella, M. Magni et al., “Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli,” *Blood*, vol. 99, no. 10, pp. 3838–3843, 2002.

[38] S.-H. Yang, M.-J. Park, I.-H. Yoon et al., “Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10,” *Experimental & Molecular Medicine*, vol. 41, no. 5, pp. 315–324, 2009.

[39] K. N. Sivanathan, S. Gronthos, D. Rojas-Canales, B. Thierry, and P. T. Coates, “Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation,” *Stem Cell Reviews and Reports*, vol. 10, no. 3, pp. 351–375, 2014.

[40] A. El-Sehemy, A. C. Chang, A. K. Azad et al., “Notch activation augments nitric oxide/soluble guanylyl cyclase signaling in immortalized ovarian surface epithelial cells and ovarian cancer cells,” *Cellular Signalling*, vol. 25, no. 12, pp. 2780–2787, 2013.